1 min read
Generation of Agonist and Antagonist Human Monoclonal Antibodies Against an Immune Checkpoint Target from the H2L2 Mouse
By Antibody Solutions Research Team on Apr 30, 2018 12:38:00 PM
Immunization of transgenic animals producing human antibodies is by far the most successful approach to obtaining “fully human” therapeutic antibodies. They allow for the rapid generation of candidate antibodies and the ability to transition lead candidates to clinical development without undergoing time consuming steps such as humanization or affinity maturation of antibodies from structural display libraries. In collaboration with Harbour Biomed and utilizing transgenic Harbour H2L2TM mice, Antibody Solutions has generated therapeutic human monoclonal antibody candidates against an immune checkpoint membrane protein target, designated “HBM-1”.
Topics: Transgenic Animals Posters Fully Human
1 min read
Therapeutic Antibody Discovery at Antibody Solutions using the OmniAbTM Platform
By Antibody Solutions Research Team on Apr 29, 2018 1:42:00 PM
Antibody Solutions performed its first program in OmniAbTM animals in September of 2012. In our 6.5 year history with OminAb animals we have worked with >1000 animals for 27 clients. The purpose of this poster is to update Antibody Solutions history of work with OmniAb animals with an emphasis on work performed in
Topics: Posters OmniAb
1 min read
Optimization of Therapeutic Discovery Strategies for Human Antibody Transgenic Animal Platforms
By Antibody Solutions Research Team on Apr 8, 2018 10:55:00 AM
Immunization of transgenic animals producing human antibodies has been the most successful approach to obtaining fully human therapeutic antibodies. They allow for the rapid generation of candidate antibodies to multiple targets of interest and the ability to transition lead candidates to clinical development without undergoing time consuming and costly steps such as humanization or affinity maturation of antibodies from structural display libraries.
Topics: Transgenic Animals Posters Human Therapeutic Antibodies
1 min read
Next-Generation Therapeutic Antibody Discovery from Single B-cells
By Antibody Solutions Research Team on Jan 8, 2018 1:39:00 PM
The most robust strategy for therapeutic antibody discovery continues to be through the use of immunized animals and the ability to isolate, interrogate, and/or immortalize immune B-cells. However, capturing the full repertoire of an immunized animal is a challenge that has come to the forefront, particularly as more difficult therapeutic targets have become the industry focus. Various technologies exist for immortalizing and interrogating immune B-cells, though each strategy presents distinct advantages and disadvantages. To this end, Antibody Solutions and Single Cell Technology (SCT) have launched a partnership to integrate SCT’s pioneering single B-cell analysis technology with Antibody Solutions’ comprehensive antibody discovery platform.
Topics: Antibody Discovery Posters Immune B-cells
1 min read
Generation and Selection of Human Monoclonal Antibodies from the H2L2 Mouse
By Antibody Solutions Research Team on Jan 8, 2018 1:33:00 PM
Human antibody-producing transgenic H2L2TM mice have been used to generate monoclonal antibodies to therapeutic targets. Transgenic animals producing human antibodies are by far the most successful approach to obtaining “fully human” therapeutic antibodies. This is largely due to the ability to move transgenic animalderived human antibodies from lead selection directly to clinical development without undergoing lead optimization steps common with humanization of murine Abs or affinity maturation of Abs from phage or other synthetic libraries.
Topics: Posters Transgenic H2L2 Mice
1 min read
Development of Antibody and PK and ADA Assays for a Cystine Knot Fusion Protein
By Antibody Solutions Research Team on Jan 1, 2018 12:00:00 AM
Cystine knot peptides, also know as knottins, are an emerging class of biotherapeutic molecules that can be engineered to bind to a diverse range of targets. Much like therapeutic antibodies, there is a need to develop critical reagents for pharmacokinetic (PK) and immunogenicity assays to support preclinical development, though this new class of molecules can present different challenges and considerations for reagent discovery. To this end, monoclonal and polyclonal reagent antibodies against a cystine-knot fusion protein (CKFP) were generated and used for PK and ADA assay development.
Topics: Posters Knottins Cystine Knot Peptides
1 min read
Discovery of Therapeutic Antibodies to Difficult Membrane Proteins
By Antibody Solutions Research Team on Dec 11, 2016 1:11:00 PM
Multi-pass trans-membrane and multimeric membrane proteins are targets for the development of therapeutic monoclonal antibodies. However, they present challenges for expression, antibody generation and screening. Success requires a multi-faceted approach with the following key elements:
- A system for stable expression of the membrane target protein, at high levels, in a variety of cell lines.
- The ability to generate immunogens that present a native, bio-active state with appropriate quaternary structure. Potential immunogens include peptides, soluble protein domains, nanodiscs, proteoliposomes, intact cells, and DNA vectors.
- Effective immunization protocols tailored to the immunogens.
- A robust platform for capturing the antibody response.
- A high-throughput screening platform for detecting antibodies on target protein-expressing cells
Topics: Posters Multi-pass transmembrane Multi-meric Membrane Therapeutic Monoclonal Antibodies
1 min read
Discovery Platform for Therapeutic D-Proteins
By Antibody Solutions Research Team on Dec 11, 2016 12:55:00 PM
Stereochemistry is a fundamental property of proteins that defines their shape and biologic function. Proteins made of L-amino acids have inherent limitations as drugs since they are degraded by proteases which reduce their halflife and are often neutralized by an immune reaction to the protein. Therapeutic proteins made of D-amino acids overcome these limitations since they are inherently resistant to degradation by proteases and have dramatically reduced immunogenicity. Results for VEGF-A and additional therapeutic target proteins are presented
Topics: Posters Stereochemistry L-amino acids
1 min read
Development of Antibodies and ELISAs to measure Free and Total Obiltoxaximab (ETI-204) in the Presence of Anthrax Protective Antigen PA63
By Antibody Solutions Research Team on Jun 8, 2015 1:15:00 PM
Preclinical and clinical pharmacokinetic (PK) studies require highly specific and high affinity immunoassays to evaluate the safety and efficacy of therapeutic monoclonal antibodies (MAbs). In addition to the requirement that immunoassays specifically detect therapeutic MAbs without interference from host serum proteins, it is increasingly critical to develop reagents that allow differentiation between Free (Unbound) and Total (Bound + Unbound) drug. These reagents help to more fully characterize in vivo drug:target interaction and illustrate the full pharmacologic effect of therapeutic MAbs.
Topics: Posters Therapeutic Monoclonal Antibodies Pharmacokinetic (PK) ELISAs
1 min read
Obtaining Antibodies to Difficult Membrane Targets through DNA and Cell Immunization
By Antibody Solutions Research Team on Jan 5, 2015 10:22:00 AM
Multi-pass transmembrane and multi-meric membrane proteins are targets for the development of therapeutic monoclonal antibodies, but are often challenging or impossible to express in a native, bio-active state with appropriate quaternary structure. Immunization with surrogate forms of the target including peptides, soluble protein domains, proteo-liposomes, or intact cells are not always successful in producing antibodies that are capable of binding to native state proteins.
Topics: Posters Multi-pass transmembrane Multi-meric Membrane Therapeutic Monoclonal Antibodies
Filter by Keyword
- Posters (21)
- Publications (15)
- Therapeutic Monoclonal Antibodies (4)
- Monoclonal (3)
- Multi-meric Membrane (3)
- Multi-pass transmembrane (3)
- Transgenic Animals (3)
- ELISAs (2)
- Human Therapeutic Antibodies (2)
- Hybridoma (2)
- SARS-CoV-2 (2)
- APOBEC3G (1)
- ARMER (1)
- ATX-GX (1)
- Alloy Therapeutics (1)
- Antibody Discovery (1)
- Antibody Generation (1)
- BRCA2 (1)
- CEM15 (1)
- Cadherin-11 (1)
- Carcinogenesis (1)
- Conditioned Media (1)
- Critical Reagents (1)
- Cystine Knot Peptides (1)
- D Protein (1)
- DLL4 (1)
- Fully Human (1)
- HIV-1 (1)
- HSA (1)
- IL-1 alpha (1)
- Immune B-cells (1)
- Immunization (1)
- Knottins (1)
- L-amino acids (1)
- L-selectin (1)
- LAM (1)
- LBAs (1)
- LOXL2 (1)
- Lymphangioleiomyomatosis (1)
- McAbs (1)
- OmniAb (1)
- OmniRat (1)
- PNAd (1)
- Pharmacokinetic (PK) (1)
- Prolactin (1)
- Secretion Capture Report Web (1)
- Stereochemistry (1)
- Therapeutic Targets (1)
- Tissue Culture (1)
- Transgenic H2L2 Mice (1)
- VEGF-A (1)
- VEGF-C (1)
- VEGF-D (1)
- p53 (1)